Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement

Dow Jones

08/18

By Connor Hart

Adaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026.

Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products.

As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology.

Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement.

Shares of Adaptive fall 1.7% in premarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

August 18, 2025 08:53 ET (12:53 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560190018"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560190018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560190018?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560190018","market":"sg","top_or_hot":-1,"title":"Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n</p>\n<p>\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n</p>\n<p>\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n</p>\n<p>\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n</p>\n<p>\n  Shares of Adaptive fall 1.7% in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies, Genentech to Terminate Strategic Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-18 20:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n</p>\n<p>\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n</p>\n<p>\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n</p>\n<p>\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n</p>\n<p>\n  Shares of Adaptive fall 1.7% in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560190018","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560190018","pubTimestamp":1755521580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Adaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026.Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products.As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology.Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement.Shares of Adaptive fall 1.7% in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4007":"制药","RHHBY":"罗氏控股","ADPT":"Adaptive Biotechnologies Corp","03165":"华夏欧优股对冲"},"translate_title":"Adaptive Biotechnologies与基因泰克终止战略协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"ADPT":0.9,"RHHBY":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nAdaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n\n\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n\n\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n\n\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n\n\n  Shares of Adaptive fall 1.7% in premarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 08:53 ET (12:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}